Phio Pharmaceuticals Corp

PHIO

Company Profile

  • Business description

    Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

  • Contact

    411 Swedeland Road
    Suite 23-1080
    King of PrussiaPA19406
    USA

    T: +1 610 947-0251

    E: [email protected]

    https://www.phiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    6

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE22,836.31458.44-1.97%
NASDAQ24,429.88101.500.42%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers